Generated by Meeveem AI
"Pioneering fibroblast immunology to treat cancer and inflammatory diseases"
Mestag develops first-in-class antibody therapies targeting fibroblast immunology to treat cancer and inflammatory diseases. The company focuses on patients who do not respond to current treatments, where 50 to 70 percent of cancer patients and 60 percent of inflammatory disease patients fail to achieve lasting remission. By redirecting fibroblast interactions with the immune system, Mestag restores immune function. The lead programme, MST-0312, induces tertiary lymphoid structures in solid tumours. The M402 programme targets diseases including rheumatoid arthritis and lupus by dampening overactive immune cells. Backed by leading investors and scientific founders, Mestag is advancing rapidly towards clinical trials.
35
Team Members
2020
Founded
Biotechnology
Sector
Hybrid
Work Environment
A future where patients with cancer and inflammatory disease who do not respond to current therapies benefit from treatments that harness fibroblast immunology to restore immune function and achieve lasting clinical outcomes.
At Mestag, our mission is to develop impactful new medicines for patients by targeting activated fibroblast populations and their role in influencing immune responses in cancer and inflammatory disease.